ST Pharm, Groundbreaking Ceremony for 2nd Oligo Plant... "Will Achieve 1 Trillion Won in Sales"

Annual Production Capacity of Up to 7 Tons

ST Pharm announced on the 19th that it held a groundbreaking ceremony for its 2nd Oligo Building on the site of the Banwol Campus in Ansan, Gyeonggi Province on the 18th. The company’s strategy is to become the world’s number one in the oligo contract development and manufacturing organization (CDMO) sector through the 2nd Oligo Building.

ST Pharm held a groundbreaking ceremony for the 2nd Oligo Building on the site of the Banwol Campus in Ansan, Gyeonggi-do on the 18th. Jang Soon-gi, Head of Production at ST Pharm; Kim Min-young, President of Dong-A ST; Jeong Jae-hoon, President of Dong-A Socio Holdings; Kang Jung-seok, Chairman of Dong-A Socio Group; Kim Kyung-jin, President of ST Pharm; Baek Sang-hwan, President of Dong-A Pharmaceutical; and Park Yoon, President of Aven General Construction, are taking a commemorative photo. (From left) [Photo by ST Pharm]

The groundbreaking ceremony was attended by Dong-A Socio Group Chairman Kang Jung-seok, ST Pharm President Kim Kyung-jin, Dong-A Socio Holdings President Jung Jae-hoon, Dong-A ST President Kim Min-young, Dong-A Pharmaceutical President Baek Sang-hwan, and other group company presidents.

ST Pharm has planned an initial investment of 110 billion KRW for the construction of the 2nd Oligo Building. Once the 2nd Oligo Building is completed and two subsequent expansions are finished, the production scale is expected to increase to about 14 mol (approximately 2.3 to 7 tons), making it the world’s largest oligo production capacity company.

The 2nd Oligo Building will be constructed by Aven General Construction, a specialized builder of current Good Manufacturing Practice (cGMP) facilities, on the Banwol Campus site with a total floor area of approximately 3,300 pyeong (10,900 cubic meters). Production facilities will be established from the 1st to the 5th floors, while the 6th and 7th floors will be reserved as spare space to be utilized according to future market growth.

ST Pharm plans to introduce an automation system in the 2nd Oligo Building. From the design stage, the layout was created with the goal of operational efficiency and automation, including analyzing worker movement paths. Additionally, process manufacturing equipment control (PCS), building management system (BMS), and warehouse management system (WMS) will be operated to improve production efficiency and reduce costs.

From an ESG (Environmental, Social, and Governance) perspective, systems such as waste heat reuse for heating, a distillation system that does not require cooling water, a washing system that minimizes water consumption, and new technologies that extend filter lifespan have been introduced.

Sales are also expected to increase in line with the growing production scale. ST Pharm anticipates that once the 2nd Oligo Building is fully operational, oligo sales will reach 1 trillion KRW by 2030.

An ST Pharm official stated, "The 2nd Oligo Building aims to enhance production efficiency. While doubling production capacity itself, it is designed to increase production efficiency by 4 to 5 times. Through this expansion, we will strive to attract more customers and achieve strong performance."

Meanwhile, according to Brandessence Market Research last year, the oligonucleotide therapeutic market is expected to grow from approximately 9.7 trillion KRW in 2021 at an average annual growth rate of 17.4%, reaching a scale of 30 trillion KRW by 2028.

This content was produced with the assistance of AI translation services.